APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting PEG-rhG-CSF

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Long-acting PEG-rhG-CSF Market Analysis and Forecast 2026-2032

23 December 2025196 pages

Choose your research edition.

Industry ResearchLong-acting PEG-rhG-CSF Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting PEG-rhG-CSF Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Long-acting PEG-rhG-CSF Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting PEG-rhG-CSF Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting PEG-rhG-CSF Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Long-acting PEG-rhG-CSF market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Long-acting PEG-rhG-CSF is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Long-acting PEG-rhG-CSF is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Long-acting PEG-rhG-CSF is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Long-acting PEG-rhG-CSF is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Long-acting PEG-rhG-CSF include CSPC, Sandoz (Novartis), Qilu Pharmaceutical, Mylan, Pfizer, Jiangsu Hengrui Medicine, Fresenius Kabi, Amgen Inc. and Coherus BioSciences, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Long-acting PEG-rhG-CSF, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Long-acting PEG-rhG-CSF, also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting PEG-rhG-CSF, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-acting PEG-rhG-CSF sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Long-acting PEG-rhG-CSF market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Long-acting PEG-rhG-CSF sales, projected growth trends, production technology, application and end-user industry.

Long-acting PEG-rhG-CSF Segment by Company

CSPC

Sandoz (Novartis)

Qilu Pharmaceutical

Mylan

Pfizer

Jiangsu Hengrui Medicine

Fresenius Kabi

Amgen Inc.

Coherus BioSciences, Inc.

Biocon Biologics Inc.

Long-acting PEG-rhG-CSF Segment by Type

Innovative Drugs

Generic Drugs

Long-acting PEG-rhG-CSF Segment by Application

Blood Disorders

Neoplastic Diseases

Others

Long-acting PEG-rhG-CSF Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting PEG-rhG-CSF market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting PEG-rhG-CSF and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting PEG-rhG-CSF.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Long-acting PEG-rhG-CSF in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Long-acting PEG-rhG-CSF manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting PEG-rhG-CSF sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Long-acting PEG-rhG-CSF Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Innovative Drugs Major Manufacturers Table 3. Generic Drugs Major Manufacturers Table 4. Global Long-acting PEG-rhG-CSF Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Blood Disorders Major Manufacturers Table 6. Neoplastic Diseases Major Manufacturers Table 7. Others Major Manufacturers Table 8. Long-acting PEG-rhG-CSF Industry Trends Table 9. Long-acting PEG-rhG-CSF Industry Drivers Table 10. Long-acting PEG-rhG-CSF Industry Opportunities and Challenges Table 11. Long-acting PEG-rhG-CSF Industry Restraints Table 12. Global Long-acting PEG-rhG-CSF Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Long-acting PEG-rhG-CSF Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Long-acting PEG-rhG-CSF Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Long-acting PEG-rhG-CSF Revenue Market Share by Region (2021-2026) Table 16. Global Long-acting PEG-rhG-CSF Revenue Market Share by Region (2027-2032) Table 17. Global Long-acting PEG-rhG-CSF Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (units) Table 18. Global Long-acting PEG-rhG-CSF Sales by Region (2021-2026) & (units) Table 19. Global Long-acting PEG-rhG-CSF Sales by Region (2027-2032) & (units) Table 20. Global Long-acting PEG-rhG-CSF Sales Market Share by Region (2021-2026) Table 21. Global Long-acting PEG-rhG-CSF Sales Market Share by Region (2027-2032) Table 22. Global Long-acting PEG-rhG-CSF Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Long-acting PEG-rhG-CSF Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Long-acting PEG-rhG-CSF Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Long-acting PEG-rhG-CSF Sales Market Share by Manufacturers (2021-2026) Table 26. Global Long-acting PEG-rhG-CSF Sales Price (USD/unit) of Manufacturers (2021-2026) Table 27. Global Long-acting PEG-rhG-CSF Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Long-acting PEG-rhG-CSF Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Long-acting PEG-rhG-CSF Manufacturers, Product Type & Application Table 30. Global Long-acting PEG-rhG-CSF Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Long-acting PEG-rhG-CSF by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Long-acting PEG-rhG-CSF Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Long-acting PEG-rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Long-acting PEG-rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Long-acting PEG-rhG-CSF Revenue Market Share by Type (2021-2026) Table 37. Global Long-acting PEG-rhG-CSF Revenue Market Share by Type (2027-2032) Table 38. Global Long-acting PEG-rhG-CSF Sales by Type 2021 VS 2025 VS 2032 (units) Table 39. Global Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 40. Global Long-acting PEG-rhG-CSF Sales by Type (2027-2032) & (units) Table 41. Global Long-acting PEG-rhG-CSF Sales Market Share by Type (2021-2026) Table 42. Global Long-acting PEG-rhG-CSF Sales Market Share by Type (2027-2032) Table 43. Global Long-acting PEG-rhG-CSF Price by Type (2021-2026) & (USD/unit) Table 44. Global Long-acting PEG-rhG-CSF Price by Type (2027-2032) & (USD/unit) Table 45. Global Long-acting PEG-rhG-CSF Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Long-acting PEG-rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Long-acting PEG-rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Long-acting PEG-rhG-CSF Revenue Market Share by Application (2021-2026) Table 49. Global Long-acting PEG-rhG-CSF Revenue Market Share by Application (2027-2032) Table 50. Global Long-acting PEG-rhG-CSF Sales by Application 2021 VS 2025 VS 2032 (units) Table 51. Global Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 52. Global Long-acting PEG-rhG-CSF Sales by Application (2027-2032) & (units) Table 53. Global Long-acting PEG-rhG-CSF Sales Market Share by Application (2021-2026) Table 54. Global Long-acting PEG-rhG-CSF Sales Market Share by Application (2027-2032) Table 55. Global Long-acting PEG-rhG-CSF Price by Application (2021-2026) & (USD/unit) Table 56. Global Long-acting PEG-rhG-CSF Price by Application (2027-2032) & (USD/unit) Table 57. CSPC Company Information Table 58. CSPC Business Overview Table 59. CSPC Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 60. CSPC Long-acting PEG-rhG-CSF Product Portfolio Table 61. CSPC Recent Development Table 62. Sandoz (Novartis) Company Information Table 63. Sandoz (Novartis) Business Overview Table 64. Sandoz (Novartis) Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 65. Sandoz (Novartis) Long-acting PEG-rhG-CSF Product Portfolio Table 66. Sandoz (Novartis) Recent Development Table 67. Qilu Pharmaceutical Company Information Table 68. Qilu Pharmaceutical Business Overview Table 69. Qilu Pharmaceutical Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 70. Qilu Pharmaceutical Long-acting PEG-rhG-CSF Product Portfolio Table 71. Qilu Pharmaceutical Recent Development Table 72. Mylan Company Information Table 73. Mylan Business Overview Table 74. Mylan Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 75. Mylan Long-acting PEG-rhG-CSF Product Portfolio Table 76. Mylan Recent Development Table 77. Pfizer Company Information Table 78. Pfizer Business Overview Table 79. Pfizer Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 80. Pfizer Long-acting PEG-rhG-CSF Product Portfolio Table 81. Pfizer Recent Development Table 82. Jiangsu Hengrui Medicine Company Information Table 83. Jiangsu Hengrui Medicine Business Overview Table 84. Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 85. Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Product Portfolio Table 86. Jiangsu Hengrui Medicine Recent Development Table 87. Fresenius Kabi Company Information Table 88. Fresenius Kabi Business Overview Table 89. Fresenius Kabi Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Fresenius Kabi Long-acting PEG-rhG-CSF Product Portfolio Table 91. Fresenius Kabi Recent Development Table 92. Amgen Inc. Company Information Table 93. Amgen Inc. Business Overview Table 94. Amgen Inc. Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Amgen Inc. Long-acting PEG-rhG-CSF Product Portfolio Table 96. Amgen Inc. Recent Development Table 97. Coherus BioSciences, Inc. Company Information Table 98. Coherus BioSciences, Inc. Business Overview Table 99. Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Product Portfolio Table 101. Coherus BioSciences, Inc. Recent Development Table 102. Biocon Biologics Inc. Company Information Table 103. Biocon Biologics Inc. Business Overview Table 104. Biocon Biologics Inc. Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Biocon Biologics Inc. Long-acting PEG-rhG-CSF Product Portfolio Table 106. Biocon Biologics Inc. Recent Development Table 107. North America Long-acting PEG-rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 108. North America Long-acting PEG-rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 109. North America Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 110. North America Long-acting PEG-rhG-CSF Sales by Type (2027-2032) & (units) Table 111. North America Long-acting PEG-rhG-CSF Sales Price by Type (2021-2026) & (USD/unit) Table 112. North America Long-acting PEG-rhG-CSF Sales Price by Type (2027-2032) & (USD/unit) Table 113. North America Long-acting PEG-rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 114. North America Long-acting PEG-rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 115. North America Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 116. North America Long-acting PEG-rhG-CSF Sales by Application (2027-2032) & (units) Table 117. North America Long-acting PEG-rhG-CSF Sales Price by Application (2021-2026) & (USD/unit) Table 118. North America Long-acting PEG-rhG-CSF Sales Price by Application (2027-2032) & (USD/unit) Table 119. North America Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 121. North America Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 122. North America Long-acting PEG-rhG-CSF Sales by Country (2021 VS 2025 VS 2032) & (units) Table 123. North America Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 124. North America Long-acting PEG-rhG-CSF Sales by Country (2027-2032) & (units) Table 125. North America Long-acting PEG-rhG-CSF Sales Price by Country (2021-2026) & (USD/unit) Table 126. North America Long-acting PEG-rhG-CSF Sales Price by Country (2027-2032) & (USD/unit) Table 127. United States Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 128. Canada Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 129. Mexico Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 130. Europe Long-acting PEG-rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 131. Europe Long-acting PEG-rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 132. Europe Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 133. Europe Long-acting PEG-rhG-CSF Sales by Type (2027-2032) & (units) Table 134. Europe Long-acting PEG-rhG-CSF Sales Price by Type (2021-2026) & (USD/unit) Table 135. Europe Long-acting PEG-rhG-CSF Sales Price by Type (2027-2032) & (USD/unit) Table 136. Europe Long-acting PEG-rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Long-acting PEG-rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 139. Europe Long-acting PEG-rhG-CSF Sales by Application (2027-2032) & (units) Table 140. Europe Long-acting PEG-rhG-CSF Sales Price by Application (2021-2026) & (USD/unit) Table 141. Europe Long-acting PEG-rhG-CSF Sales Price by Application (2027-2032) & (USD/unit) Table 142. Europe Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Europe Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 144. Europe Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 145. Europe Long-acting PEG-rhG-CSF Sales by Country (2021 VS 2025 VS 2032) & (units) Table 146. Europe Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 147. Europe Long-acting PEG-rhG-CSF Sales by Country (2027-2032) & (units) Table 148. Europe Long-acting PEG-rhG-CSF Sales Price by Country (2021-2026) & (USD/unit) Table 149. Europe Long-acting PEG-rhG-CSF Sales Price by Country (2027-2032) & (USD/unit) Table 150. Germany Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 151. France Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 152. U.K. Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 153. Italy Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 154. Russia Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 155. Spain Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 156. Netherlands Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 157. Switzerland Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 158. Sweden Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 159. Poland Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 160. China Long-acting PEG-rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 161. China Long-acting PEG-rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 162. China Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 163. China Long-acting PEG-rhG-CSF Sales by Type (2027-2032) & (units) Table 164. China Long-acting PEG-rhG-CSF Sales Price by Type (2021-2026) & (USD/unit) Table 165. China Long-acting PEG-rhG-CSF Sales Price by Type (2027-2032) & (USD/unit) Table 166. China Long-acting PEG-rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 167. China Long-acting PEG-rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 168. China Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 169. China Long-acting PEG-rhG-CSF Sales by Application (2027-2032) & (units) Table 170. China Long-acting PEG-rhG-CSF Sales Price by Application (2021-2026) & (USD/unit) Table 171. China Long-acting PEG-rhG-CSF Sales Price by Application (2027-2032) & (USD/unit) Table 172. Asia Long-acting PEG-rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 173. Asia Long-acting PEG-rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 174. Asia Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 175. Asia Long-acting PEG-rhG-CSF Sales by Type (2027-2032) & (units) Table 176. Asia Long-acting PEG-rhG-CSF Sales Price by Type (2021-2026) & (USD/unit) Table 177. Asia Long-acting PEG-rhG-CSF Sales Price by Type (2027-2032) & (USD/unit) Table 178. Asia Long-acting PEG-rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 179. Asia Long-acting PEG-rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 180. Asia Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 181. Asia Long-acting PEG-rhG-CSF Sales by Application (2027-2032) & (units) Table 182. Asia Long-acting PEG-rhG-CSF Sales Price by Application (2021-2026) & (USD/unit) Table 183. Asia Long-acting PEG-rhG-CSF Sales Price by Application (2027-2032) & (USD/unit) Table 184. Asia Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. Asia Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. Asia Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. Asia Long-acting PEG-rhG-CSF Sales by Country (2021 VS 2025 VS 2032) & (units) Table 188. Asia Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 189. Asia Long-acting PEG-rhG-CSF Sales by Country (2027-2032) & (units) Table 190. Asia Long-acting PEG-rhG-CSF Sales Price by Country (2021-2026) & (USD/unit) Table 191. Asia Long-acting PEG-rhG-CSF Sales Price by Country (2027-2032) & (USD/unit) Table 192. Japan Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 193. South Korea Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 194. India Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 195. Australia Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 196. Taiwan Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 197. Southeast Asia Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 198. SAMEA Long-acting PEG-rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 199. SAMEA Long-acting PEG-rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 200. SAMEA Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 201. SAMEA Long-acting PEG-rhG-CSF Sales by Type (2027-2032) & (units) Table 202. SAMEA Long-acting PEG-rhG-CSF Sales Price by Type (2021-2026) & (USD/unit) Table 203. SAMEA Long-acting PEG-rhG-CSF Sales Price by Type (2027-2032) & (USD/unit) Table 204. SAMEA Long-acting PEG-rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 205. SAMEA Long-acting PEG-rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 206. SAMEA Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 207. SAMEA Long-acting PEG-rhG-CSF Sales by Application (2027-2032) & (units) Table 208. SAMEA Long-acting PEG-rhG-CSF Sales Price by Application (2021-2026) & (USD/unit) Table 209. SAMEA Long-acting PEG-rhG-CSF Sales Price by Application (2027-2032) & (USD/unit) Table 210. SAMEA Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 211. SAMEA Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 212. SAMEA Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 213. SAMEA Long-acting PEG-rhG-CSF Sales by Country (2021 VS 2025 VS 2032) & (units) Table 214. SAMEA Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 215. SAMEA Long-acting PEG-rhG-CSF Sales by Country (2027-2032) & (units) Table 216. SAMEA Long-acting PEG-rhG-CSF Sales Price by Country (2021-2026) & (USD/unit) Table 217. SAMEA Long-acting PEG-rhG-CSF Sales Price by Country (2027-2032) & (USD/unit) Table 218. Brazil Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 219. Argentina Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 220. Chile Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 221. Colombia Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 222. Peru Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 223. Saudi Arabia Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 224. Israel Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 225. UAE Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 226. Turkey Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 227. Iran Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 228. Egypt Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Table 229. Key Raw Materials Table 230. Raw Materials Key Suppliers Table 231. Long-acting PEG-rhG-CSF Distributors List Table 232. Long-acting PEG-rhG-CSF Customers List Table 233. Research Programs/Design for This Report Table 234. Authors List of This Report Table 235. Secondary Sources Table 236. Primary Sources List of Figures Figure 1. Long-acting PEG-rhG-CSF Image Figure 2. Global Long-acting PEG-rhG-CSF Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting PEG-rhG-CSF Market Size Share 2021 VS 2025 VS 2032 Figure 4. Innovative Drugs Image Figure 5. Generic Drugs Image Figure 6. Global Long-acting PEG-rhG-CSF Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Long-acting PEG-rhG-CSF Market Size Share 2021 VS 2025 VS 2032 Figure 8. Blood Disorders Image Figure 9. Neoplastic Diseases Image Figure 10. Others Image Figure 11. Global Long-acting PEG-rhG-CSF Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Figure 13. Global Long-acting PEG-rhG-CSF Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Long-acting PEG-rhG-CSF Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Long-acting PEG-rhG-CSF Revenue Market Share by Region (2021-2032) Figure 16. Global Long-acting PEG-rhG-CSF Sales (2021-2032) & (units) Figure 17. Global Long-acting PEG-rhG-CSF Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 18. Global Long-acting PEG-rhG-CSF Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Long-acting PEG-rhG-CSF Sales YoY (2021-2032) & (units) Figure 20. Europe Long-acting PEG-rhG-CSF Sales YoY (2021-2032) & (units) Figure 21. China Long-acting PEG-rhG-CSF Sales YoY (2021-2032) & (units) Figure 22. Asia (Excluding China) Long-acting PEG-rhG-CSF Sales YoY (2021-2032) & (units) Figure 23. South America, Middle East and Africa Long-acting PEG-rhG-CSF Sales YoY (2021-2032) & (units) Figure 24. Global Long-acting PEG-rhG-CSF Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Long-acting PEG-rhG-CSF Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Long-acting PEG-rhG-CSF Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Long-acting PEG-rhG-CSF Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Long-acting PEG-rhG-CSF Revenue Market Share by Type (2021-2032) Figure 30. Global Long-acting PEG-rhG-CSF Sales by Type (2021 VS 2025 VS 2032) & (units) Figure 31. Global Long-acting PEG-rhG-CSF Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Long-acting PEG-rhG-CSF Sales Market Share by Type (2021-2032) Figure 33. Global Long-acting PEG-rhG-CSF Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Long-acting PEG-rhG-CSF Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Long-acting PEG-rhG-CSF Revenue Market Share by Application (2021-2032) Figure 36. Global Long-acting PEG-rhG-CSF Sales by Application (2021 VS 2025 VS 2032) & (units) Figure 37. Global Long-acting PEG-rhG-CSF Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Long-acting PEG-rhG-CSF Sales Market Share by Application (2021-2032) Figure 39. North America Long-acting PEG-rhG-CSF Revenue Share by Type (2021-2032) Figure 40. North America Long-acting PEG-rhG-CSF Sales Share by Type (2021-2032) Figure 41. North America Long-acting PEG-rhG-CSF Revenue Share by Application (2021-2032) Figure 42. North America Long-acting PEG-rhG-CSF Sales Share by Application (2021-2032) Figure 43. North America Long-acting PEG-rhG-CSF Revenue Share by Country (2021-2032) Figure 44. North America Long-acting PEG-rhG-CSF Sales Share by Country (2021-2032) Figure 45. Europe Long-acting PEG-rhG-CSF Revenue Share by Type (2021-2032) Figure 46. Europe Long-acting PEG-rhG-CSF Sales Share by Type (2021-2032) Figure 47. Europe Long-acting PEG-rhG-CSF Revenue Share by Application (2021-2032) Figure 48. Europe Long-acting PEG-rhG-CSF Sales Share by Application (2021-2032) Figure 49. Europe Long-acting PEG-rhG-CSF Revenue Share by Country (2021-2032) Figure 50. Europe Long-acting PEG-rhG-CSF Sales Share by Country (2021-2032) Figure 51. China Long-acting PEG-rhG-CSF Revenue Share by Type (2021-2032) Figure 52. China Long-acting PEG-rhG-CSF Sales Share by Type (2021-2032) Figure 53. China Long-acting PEG-rhG-CSF Revenue Share by Application (2021-2032) Figure 54. China Long-acting PEG-rhG-CSF Sales Share by Application (2021-2032) Figure 55. Asia Long-acting PEG-rhG-CSF Revenue Share by Type (2021-2032) Figure 56. Asia Long-acting PEG-rhG-CSF Sales Share by Type (2021-2032) Figure 57. Asia Long-acting PEG-rhG-CSF Revenue Share by Application (2021-2032) Figure 58. Asia Long-acting PEG-rhG-CSF Sales Share by Application (2021-2032) Figure 59. Asia Long-acting PEG-rhG-CSF Revenue Share by Country (2021-2032) Figure 60. Asia Long-acting PEG-rhG-CSF Sales Share by Country (2021-2032) Figure 61. SAMEA Long-acting PEG-rhG-CSF Revenue Share by Type (2021-2032) Figure 62. SAMEA Long-acting PEG-rhG-CSF Sales Share by Type (2021-2032) Figure 63. SAMEA Long-acting PEG-rhG-CSF Revenue Share by Application (2021-2032) Figure 64. SAMEA Long-acting PEG-rhG-CSF Sales Share by Application (2021-2032) Figure 65. SAMEA Long-acting PEG-rhG-CSF Revenue Share by Country (2021-2032) Figure 66. SAMEA Long-acting PEG-rhG-CSF Sales Share by Country (2021-2032) Figure 67. Long-acting PEG-rhG-CSF Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Long-acting PEG-rhG-CSF Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Innovative Drugs
  • Generic Drugs
Applications
  • Blood Disorders
  • Neoplastic Diseases
  • Others
Companies covered
  • CSPC
  • Sandoz (Novartis)
  • Qilu Pharmaceutical
  • Mylan
  • Pfizer
  • Jiangsu Hengrui Medicine
  • Fresenius Kabi
  • Amgen Inc.
  • Coherus BioSciences, Inc.
  • Biocon Biologics Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Long-acting PEG-rhG-CSF Market by Type
  3. 1.2.1 Global Long-acting PEG-rhG-CSF Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Innovative Drugs
  5. 1.2.3 Generic Drugs
  6. 1.3 Long-acting PEG-rhG-CSF Market by Application
  7. 1.3.1 Global Long-acting PEG-rhG-CSF Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Blood Disorders
  9. 1.3.3 Neoplastic Diseases
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Long-acting PEG-rhG-CSF Market Dynamics
  1. 2.1 Long-acting PEG-rhG-CSF Industry Trends
  2. 2.2 Long-acting PEG-rhG-CSF Industry Drivers
  3. 2.3 Long-acting PEG-rhG-CSF Industry Opportunities and Challenges
  4. 2.4 Long-acting PEG-rhG-CSF Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Long-acting PEG-rhG-CSF Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Long-acting PEG-rhG-CSF Revenue by Region
  3. 3.2.1 Global Long-acting PEG-rhG-CSF Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Long-acting PEG-rhG-CSF Revenue by Region (2021-2026)
  5. 3.2.3 Global Long-acting PEG-rhG-CSF Revenue by Region (2027-2032)
  6. 3.2.4 Global Long-acting PEG-rhG-CSF Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Long-acting PEG-rhG-CSF Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Long-acting PEG-rhG-CSF Sales by Region
  9. 3.4.1 Global Long-acting PEG-rhG-CSF Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Long-acting PEG-rhG-CSF Sales by Region (2021-2026)
  11. 3.4.3 Global Long-acting PEG-rhG-CSF Sales by Region (2027-2032)
  12. 3.4.4 Global Long-acting PEG-rhG-CSF Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Long-acting PEG-rhG-CSF Revenue by Manufacturers
  2. 4.1.1 Global Long-acting PEG-rhG-CSF Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Long-acting PEG-rhG-CSF Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Long-acting PEG-rhG-CSF Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Long-acting PEG-rhG-CSF Sales by Manufacturers
  6. 4.2.1 Global Long-acting PEG-rhG-CSF Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Long-acting PEG-rhG-CSF Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Long-acting PEG-rhG-CSF Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Long-acting PEG-rhG-CSF Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Long-acting PEG-rhG-CSF Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Long-acting PEG-rhG-CSF Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Long-acting PEG-rhG-CSF Manufacturers, Product Type & Application
  13. 4.7 Global Long-acting PEG-rhG-CSF Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Long-acting PEG-rhG-CSF Market CR5 and HHI
  16. 4.8.2 2025 Long-acting PEG-rhG-CSF Tier 1, Tier 2, and Tier 3
5 Long-acting PEG-rhG-CSF Market by Type
  1. 5.1 Global Long-acting PEG-rhG-CSF Revenue by Type
  2. 5.1.1 Global Long-acting PEG-rhG-CSF Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Long-acting PEG-rhG-CSF Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Long-acting PEG-rhG-CSF Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Long-acting PEG-rhG-CSF Sales by Type
  6. 5.2.1 Global Long-acting PEG-rhG-CSF Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting PEG-rhG-CSF Sales by Type (2021-2032) & (units)
  8. 5.2.3 Global Long-acting PEG-rhG-CSF Sales Market Share by Type (2021-2032)
  9. 5.3 Global Long-acting PEG-rhG-CSF Price by Type
6 Long-acting PEG-rhG-CSF Market by Application
  1. 6.1 Global Long-acting PEG-rhG-CSF Revenue by Application
  2. 6.1.1 Global Long-acting PEG-rhG-CSF Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Long-acting PEG-rhG-CSF Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Long-acting PEG-rhG-CSF Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Long-acting PEG-rhG-CSF Sales by Application
  6. 6.2.1 Global Long-acting PEG-rhG-CSF Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Long-acting PEG-rhG-CSF Sales by Application (2021-2032) & (units)
  8. 6.2.3 Global Long-acting PEG-rhG-CSF Sales Market Share by Application (2021-2032)
  9. 6.3 Global Long-acting PEG-rhG-CSF Price by Application
7 Company Profiles
  1. 7.1 CSPC
  2. 7.1.1 CSPC Company Information
  3. 7.1.2 CSPC Business Overview
  4. 7.1.3 CSPC Long-acting PEG-rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 CSPC Long-acting PEG-rhG-CSF Product Portfolio
  6. 7.1.5 CSPC Recent Developments
  7. 7.2 Sandoz (Novartis)
  8. 7.2.1 Sandoz (Novartis) Company Information
  9. 7.2.2 Sandoz (Novartis) Business Overview
  10. 7.2.3 Sandoz (Novartis) Long-acting PEG-rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sandoz (Novartis) Long-acting PEG-rhG-CSF Product Portfolio
  12. 7.2.5 Sandoz (Novartis) Recent Developments
  13. 7.3 Qilu Pharmaceutical
  14. 7.3.1 Qilu Pharmaceutical Company Information
  15. 7.3.2 Qilu Pharmaceutical Business Overview
  16. 7.3.3 Qilu Pharmaceutical Long-acting PEG-rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Qilu Pharmaceutical Long-acting PEG-rhG-CSF Product Portfolio
  18. 7.3.5 Qilu Pharmaceutical Recent Developments
  19. 7.4 Mylan
  20. 7.4.1 Mylan Company Information
  21. 7.4.2 Mylan Business Overview
  22. 7.4.3 Mylan Long-acting PEG-rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Mylan Long-acting PEG-rhG-CSF Product Portfolio
  24. 7.4.5 Mylan Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Long-acting PEG-rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Long-acting PEG-rhG-CSF Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Jiangsu Hengrui Medicine
  32. 7.6.1 Jiangsu Hengrui Medicine Company Information
  33. 7.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 7.6.3 Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Product Portfolio
  36. 7.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 7.7 Fresenius Kabi
  38. 7.7.1 Fresenius Kabi Company Information
  39. 7.7.2 Fresenius Kabi Business Overview
  40. 7.7.3 Fresenius Kabi Long-acting PEG-rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Fresenius Kabi Long-acting PEG-rhG-CSF Product Portfolio
  42. 7.7.5 Fresenius Kabi Recent Developments
  43. 7.8 Amgen Inc.
  44. 7.8.1 Amgen Inc. Company Information
  45. 7.8.2 Amgen Inc. Business Overview
  46. 7.8.3 Amgen Inc. Long-acting PEG-rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Amgen Inc. Long-acting PEG-rhG-CSF Product Portfolio
  48. 7.8.5 Amgen Inc. Recent Developments
  49. 7.9 Coherus BioSciences, Inc.
  50. 7.9.1 Coherus BioSciences, Inc. Company Information
  51. 7.9.2 Coherus BioSciences, Inc. Business Overview
  52. 7.9.3 Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Product Portfolio
  54. 7.9.5 Coherus BioSciences, Inc. Recent Developments
  55. 7.10 Biocon Biologics Inc.
  56. 7.10.1 Biocon Biologics Inc. Company Information
  57. 7.10.2 Biocon Biologics Inc. Business Overview
  58. 7.10.3 Biocon Biologics Inc. Long-acting PEG-rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Biocon Biologics Inc. Long-acting PEG-rhG-CSF Product Portfolio
  60. 7.10.5 Biocon Biologics Inc. Recent Developments
8 North America
  1. 8.1 North America Long-acting PEG-rhG-CSF Market Size by Type
  2. 8.1.1 North America Long-acting PEG-rhG-CSF Revenue by Type (2021-2032)
  3. 8.1.2 North America Long-acting PEG-rhG-CSF Sales by Type (2021-2032)
  4. 8.1.3 North America Long-acting PEG-rhG-CSF Price by Type (2021-2032)
  5. 8.2 North America Long-acting PEG-rhG-CSF Market Size by Application
  6. 8.2.1 North America Long-acting PEG-rhG-CSF Revenue by Application (2021-2032)
  7. 8.2.2 North America Long-acting PEG-rhG-CSF Sales by Application (2021-2032)
  8. 8.2.3 North America Long-acting PEG-rhG-CSF Price by Application (2021-2032)
  9. 8.3 North America Long-acting PEG-rhG-CSF Market Size by Country
  10. 8.3.1 North America Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Long-acting PEG-rhG-CSF Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Long-acting PEG-rhG-CSF Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Long-acting PEG-rhG-CSF Market Size by Type
  2. 9.1.1 Europe Long-acting PEG-rhG-CSF Revenue by Type (2021-2032)
  3. 9.1.2 Europe Long-acting PEG-rhG-CSF Sales by Type (2021-2032)
  4. 9.1.3 Europe Long-acting PEG-rhG-CSF Price by Type (2021-2032)
  5. 9.2 Europe Long-acting PEG-rhG-CSF Market Size by Application
  6. 9.2.1 Europe Long-acting PEG-rhG-CSF Revenue by Application (2021-2032)
  7. 9.2.2 Europe Long-acting PEG-rhG-CSF Sales by Application (2021-2032)
  8. 9.2.3 Europe Long-acting PEG-rhG-CSF Price by Application (2021-2032)
  9. 9.3 Europe Long-acting PEG-rhG-CSF Market Size by Country
  10. 9.3.1 Europe Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Long-acting PEG-rhG-CSF Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Long-acting PEG-rhG-CSF Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Long-acting PEG-rhG-CSF Market Size by Type
  2. 10.1.1 China Long-acting PEG-rhG-CSF Revenue by Type (2021-2032)
  3. 10.1.2 China Long-acting PEG-rhG-CSF Sales by Type (2021-2032)
  4. 10.1.3 China Long-acting PEG-rhG-CSF Price by Type (2021-2032)
  5. 10.2 China Long-acting PEG-rhG-CSF Market Size by Application
  6. 10.2.1 China Long-acting PEG-rhG-CSF Revenue by Application (2021-2032)
  7. 10.2.2 China Long-acting PEG-rhG-CSF Sales by Application (2021-2032)
  8. 10.2.3 China Long-acting PEG-rhG-CSF Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Long-acting PEG-rhG-CSF Market Size by Type
  2. 11.1.1 Asia Long-acting PEG-rhG-CSF Revenue by Type (2021-2032)
  3. 11.1.2 Asia Long-acting PEG-rhG-CSF Sales by Type (2021-2032)
  4. 11.1.3 Asia Long-acting PEG-rhG-CSF Price by Type (2021-2032)
  5. 11.2 Asia Long-acting PEG-rhG-CSF Market Size by Application
  6. 11.2.1 Asia Long-acting PEG-rhG-CSF Revenue by Application (2021-2032)
  7. 11.2.2 Asia Long-acting PEG-rhG-CSF Sales by Application (2021-2032)
  8. 11.2.3 Asia Long-acting PEG-rhG-CSF Price by Application (2021-2032)
  9. 11.3 Asia Long-acting PEG-rhG-CSF Market Size by Country
  10. 11.3.1 Asia Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Long-acting PEG-rhG-CSF Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Long-acting PEG-rhG-CSF Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Long-acting PEG-rhG-CSF Market Size by Type
  2. 12.1.1 SAMEA Long-acting PEG-rhG-CSF Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Long-acting PEG-rhG-CSF Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Long-acting PEG-rhG-CSF Price by Type (2021-2032)
  5. 12.2 SAMEA Long-acting PEG-rhG-CSF Market Size by Application
  6. 12.2.1 SAMEA Long-acting PEG-rhG-CSF Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Long-acting PEG-rhG-CSF Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Long-acting PEG-rhG-CSF Price by Application (2021-2032)
  9. 12.3 SAMEA Long-acting PEG-rhG-CSF Market Size by Country
  10. 12.3.1 SAMEA Long-acting PEG-rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Long-acting PEG-rhG-CSF Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Long-acting PEG-rhG-CSF Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Long-acting PEG-rhG-CSF Value Chain Analysis
  2. 13.1.1 Long-acting PEG-rhG-CSF Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Long-acting PEG-rhG-CSF Production Mode & Process
  6. 13.2 Long-acting PEG-rhG-CSF Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Long-acting PEG-rhG-CSF Distributors
  9. 13.2.3 Long-acting PEG-rhG-CSF Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst